Zacks: Analysts Expect Dynavax Technologies Corporation (DVAX) Will Post Earnings of $0.30 Per Share
Equities analysts expect that Dynavax Technologies Corporation (NASDAQ:DVAX) will post earnings per share of $0.30 for the current quarter, according to Zacks. Two analysts have made estimates for Dynavax Technologies’ earnings. The highest EPS estimate is $0.95 and the lowest is ($0.35). Dynavax Technologies reported earnings per share of ($0.56) during the same quarter last year, which would indicate a positive year over year growth rate of 153.6%. The business is expected to announce its next quarterly earnings results on Monday, March 12th.
According to Zacks, analysts expect that Dynavax Technologies will report full year earnings of ($1.36) per share for the current financial year, with EPS estimates ranging from ($1.75) to ($0.25). For the next financial year, analysts expect that the firm will post earnings of ($1.19) per share, with EPS estimates ranging from ($1.65) to ($0.59). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.15. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The firm had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.28 million. During the same quarter last year, the business posted ($0.90) EPS. Dynavax Technologies’s revenue was down 68.8% on a year-over-year basis.
Several institutional investors and hedge funds have recently modified their holdings of DVAX. Swiss National Bank grew its position in Dynavax Technologies by 25.5% during the 2nd quarter. Swiss National Bank now owns 70,978 shares of the biopharmaceutical company’s stock worth $685,000 after acquiring an additional 14,400 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Dynavax Technologies by 24.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 155,095 shares of the biopharmaceutical company’s stock worth $1,496,000 after buying an additional 30,036 shares during the period. Patriot Financial Group Insurance Agency LLC lifted its stake in shares of Dynavax Technologies by 50.0% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 18,000 shares of the biopharmaceutical company’s stock valued at $419,000 after purchasing an additional 6,000 shares during the period. New York State Common Retirement Fund lifted its stake in shares of Dynavax Technologies by 29.4% in the 2nd quarter. New York State Common Retirement Fund now owns 52,400 shares of the biopharmaceutical company’s stock valued at $506,000 after purchasing an additional 11,899 shares during the period. Finally, Lord Abbett & CO. LLC acquired a new position in shares of Dynavax Technologies in the 2nd quarter valued at about $7,777,000. Institutional investors own 70.61% of the company’s stock.
Shares of Dynavax Technologies (NASDAQ DVAX) opened at $18.40 on Friday. Dynavax Technologies has a 1-year low of $3.70 and a 1-year high of $24.45.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.